

Yafei Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7780142/publications.pdf>

Version: 2024-02-01

39
papers

424
citations

1040056

9
h-index

839539

18
g-index

40
all docs

40
docs citations

40
times ranked

747
citing authors

#	ARTICLE	IF	CITATIONS
1	c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 92-99.	0.8	73
2	Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 365.	17.1	50
3	IRE1 α -XBP1 signaling pathway, a potential therapeutic target in multiple myeloma. <i>Leukemia Research</i> , 2016, 49, 7-12.	0.8	42
4	Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 334.	3.5	26
5	High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin's lymphoma in China. <i>Annals of Hematology</i> , 2018, 97, 453-457.	1.8	25
6	Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. <i>Frontiers in Immunology</i> , 2021, 12, 720571.	4.8	25
7	Clinical characteristics of 26 patients with primary extranodal Hodgkin lymphoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 5045-50.	0.5	16
8	Toll-like receptor 4-induced inflammatory responses contribute to the tumor-associated macrophages formation and infiltration in patients with diffuse large B-cell lymphoma. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 232-238.	1.3	12
9	Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	12
10	Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis. <i>Bioscience Reports</i> , 2018, 38, .	2.4	9
11	The Lymphocyte-Monocyte Ratio and the Platelet-Lymphocyte Ratio at Diagnosis as Independent Prognostic Factors in Primary Gastrointestinal Diffuse Large B Cell Lymphoma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 333-341.	0.6	8
12	Novel prognostic scoring system for diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2018, 15, 5325-5332.	1.8	8
13	Clinical characteristics and prognosis associated with multiple primary malignant tumors in non-Hodgkin lymphoma patients. <i>Tumori</i> , 2019, 105, 474-482.	1.1	8
14	RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients. <i>Journal of Cancer</i> , 2020, 11, 3543-3550.	2.5	8
15	Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7504-7504.	1.6	8
16	Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8050-8050.	1.6	8
17	A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified. <i>Leukemia Research</i> , 2018, 73, 5-11.	0.8	7
18	BCAR3 promotes head and neck cancer growth and is associated with poor prognosis. <i>Cell Death Discovery</i> , 2021, 7, 316.	4.7	7

#	ARTICLE	IF	CITATIONS
19	ALK-positive anaplastic large cell lymphoma with prominent bone involvement. <i>British Journal of Haematology</i> , 2015, 170, 443-443.	2.5	6
20	Multiple myeloma with dural mater involvement. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3373-3375.	2.0	6
21	HES1 is an independent prognostic factor for acute myeloid leukemia. <i>OncoTargets and Therapy</i> , 2015, 8, 899.	2.0	5
22	Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients. <i>Scientific Reports</i> , 2021, 11, 4273.	3.3	5
23	Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma. <i>Clinical and Experimental Medicine</i> , 2022, 22, 183-191.	3.6	5
24	miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2020, 19, 3487-3494.	1.8	5
25	Phosphorylation of MICAL2 by ARG promotes head and neck cancer tumorigenesis by regulating skeletal rearrangement. <i>Oncogene</i> , 2022, 41, 334-346.	5.9	5
26	Downregulation of <i>FAPP2</i> gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T-cell acute lymphoblastic leukemia. <i>Hematological Oncology</i> , 2022, 40, 249-257.	1.7	5
27	Radioprotective effect of a pan-caspase inhibitor in a novel model of radiation injury to the nucleus of the abducens nerve. <i>Molecular Medicine Reports</i> , 2014, 10, 1433-1437.	2.4	4
28	ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy. <i>OncoTargets and Therapy</i> , 2016, 9, 265.	2.0	4
29	Comorbidity as an independent prognostic factor in elderly patients with peripheral T-cell lymphoma. <i>OncoTargets and Therapy</i> , 2016, 9, 1795.	2.0	4
30	Correlation Between Uptake of 18F-FDG During PET/CT and Ki-67 Expression in Patients Newly Diagnosed With Multiple Myeloma Having Extramedullary Involvement. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381984906.	1.9	4
31	Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 785297.	2.8	4
32	Posttranslational modification of Aurora A NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma. <i>Clinical and Translational Medicine</i> , 2022, 12, e744.	4.0	4
33	Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	3
34	Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10770-10773.	3.6	2
35	Multiplex ligation-dependent probe amplification identifies copy number changes in normal and undetectable karyotype MDS patients. <i>Annals of Hematology</i> , 2021, 100, 2207-2214.	1.8	1
36	Acetabular myeloid sarcoma as an extramedullary presentation of chronic myeloid leukaemia blast crisis. <i>British Journal of Haematology</i> , 2019, 186, 650-650.	2.5	0

#	ARTICLE	IF	CITATIONS
37	Modified Conditioning Regimen with Idarubicin Prior to Autologous Hematopoietic Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphoma. Blood, 2019, 134, 5349-5349.	1.4	0
38	Management of Primary Gastrointestinal Non-Hodgkin Lymphoma with Lenalidomide. Blood, 2019, 134, 5354-5354.	1.4	0
39	Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients. Blood, 2021, 138, 4783-4783.	1.4	0